Icariin, a phoshphodiesterase-5 inhibitor, improves learning and memory in APP/PS1 transgenic mice by stimulation of NO/cGMP signalling

International Journal of Neuropsychopharmacology

Volumn 17, Issue 6, 2014, Pages 871-881

  Jin, Feng ^a,b   Gong, Qi Hai ^a   Xu, Ya Sha ^a   Wang, Li Na ^a   Jin, Hai ^a   Li, Fei ^a   Li, Li Sheng ^a   Ma, Yue Ming ^b   Shi, Jing Shan ^a,b  

^a ZUNYI MEDICAL UNIVERSITY   (China)

^b SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Alzheimer's disease; Icariin; NO cGMP signalling; NOS; PDE5

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; CYCLIC GMP; ICARIIN; MESSENGER RNA; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PHOSPHODIESTERASE V; PRESENILIN 1; SILDENAFIL; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); APP PROTEIN, HUMAN; FLAVONOID; NOOTROPIC AGENT; PDE5A PROTEIN, MOUSE; PEPTIDE FRAGMENT; PHOSPHODIESTERASE V INHIBITOR; PSEN1 PROTEIN, HUMAN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; HIPPOCAMPUS; LEARNING; MALE; MEMORY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENIC MOUSE; ANIMAL; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; GENETICS; HUMAN; MAZE TEST; METABOLISM; PHYSIOLOGY; RANDOMIZATION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; CEREBRAL CORTEX; CYCLIC GMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FLAVONOIDS; HIPPOCAMPUS; HUMANS; MALE; MAZE LEARNING; MICE, TRANSGENIC; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NOOTROPIC AGENTS; PEPTIDE FRAGMENTS; PHOSPHODIESTERASE 5 INHIBITORS; PRESENILIN-1; RANDOM ALLOCATION;

EID: 84899984709     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145713001533     Document Type: Article

References (43)

1. Austin SA, Santhanam AV, Katusic ZS. (2010) Endothelial nitric oxide modulates expression and processing of amyloid precursor protein. Circ Res 107:1498-1502.
2. Austin SA, Santhanam AV, Hinton DJ, Choi DS, Katusic ZS. (2013) Endothelial nitric oxide deficiency promotes Alzheimer's disease pathology. J Neurochem. Epub ahead of print. Retrieved 8 Jun 2013. doi:10.1111/jnc.12334.
3. Balcells M, Wallins JS, Edelman ER. (2008) Amyloid beta toxicity dependent upon endothelial cell state. Neurosci Lett 441:319-322.
4. Bertram L, Tanzi RE. (2012) The genetics of Alzheimer's disease. Prog Mol Biol Transl Sci 107:79-100.
5. Bertram L, Lill CM, Tanzi RE. (2010) The genetics of Alzheimer disease: Back to the future. Neuron 68:270-281.
6. Butterfield DA, Reed T, Newman SF, Sultana R. (2007) Roles of amyloid beta-peptide-Associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment. Free Radic Biol Med 43:658-677.
7. Castellani RJ, Rolston RK, Smith MA. (2010) Alzheimer disease. Dis Mon 56:484-546.
8. Charriaut-Marlangue C, Bonnin P, Pham H, Loron G, Leger PL, Gressens P, Renolleau S, Baud O. (2013) Nitric oxide signalling in the brain: A new target for inhaled nitric oxide? Ann Neurol. Epub ahead of print. Retrieved 29 Jan 2013. doi:10.1002/ana.23842.
9. Chin J. (2011) Selecting a mouse model of Alzheimer's disease. Methods Mol Biol 670:169-189.
10. Chung BH, Kim JD, Kim CK, Kim JH, Won MH, Lee HS, Dong MS, Ha KS, Kwon YG, Kim YM. (2008) Icariin stimulates angiogenesis by activating the MEK/ERKand PI3K/Akt/eNOS-dependent signal pathways in human endothelial cells. Biochem Biophys Res Commun 376:404-408.
11. Colton CA, Vitek MP, Wink DA, Xu Q, Cantillana V, Previti ML, Van Nostrand WE, Weinberg JB, Dawson H. (2006) NO synthase 2. (NOS2) deletion promotes multiple pathologies in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 103:12867-12872.
12. Cooke RM, Mistry R, Challiss RA, Straub VA. (2013) Nitric oxide synthesis and cGMP production is important for neurite growth and synapse remodeling after axotomy. J Neurosci 33:5626-5637.
13. de Vente J. (2004) cGMP: A second messenger for acetylcholine in the brain? Neurochem Int 45:799-812.
14. Dilshara MG, Jayasooriya RG, Kang CH, Lee S, Park SR, Jeong JW, Choi YH, Seo YT, Jang YP, Kim GY. (2013) Downregulation of pro-inflammatory mediators by a water extract of Schisandra chinensis. (Turcz.) Baill fruit in lipopolysaccharide-stimulated RAW 264.7 macrophage cells. Environ Toxicol Pharmacol 36:256-264.
15. Förstermann U, Sessa WC. (2012) Nitric oxide synthases: Regulation and function. Eur Heart J 33:829-837, 837a-837d.
16. García-Osta A, Cuadrado-Tejedor M, García-Barroso C, Oyarzábal J, Franco R. (2012) Phosphodiesterases as therapeutic targets for Alzheimer's disease. ACS Chem Neurosci 3:832-844.
17. Guo J, Li F, Wu Q, Gong Q, Lu Y, Shi J. (2010) Protective effects of icariin on brain dysfunction induced by lipopolysaccharide in rats. Phytomedicine 17:950-955.
18. Guo Q, Wang Z, Li H, Wiese M, Zheng H. (2012) APP physiological and pathophysiological functions: Insights from animal models. Cell Res 22:78-89.
19. Hidaka N, Suemaru K, Takechi K, Li B, Araki H. (2011) Inhibitory effects of valproate on impairment of Y-maze alternation behavior induced by repeated electroconvulsive seizures and c-Fos protein levels in rat brains. Acta Med Okayama 65:269-277.
20. Iadecola C. (2005) Rescuing troubled vessels in Alzheimer disease. Nat Med 11:923-924.
21. Jiang Z, Hu B, Wang J, Tang Q, Tan Y, Xiang J, Liu J. (2006) Effect of icariin on cyclic GMP levels and on the mRNA expression of cGMP-binding cGMP-specific phosphodiesterase. (PDE5) in penile cavernosum. J Huazhong Univ Sci Technolog Med Sci 26:460-462.
22. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL. (1998) Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 95:6448-6453.
23. Li F, Gong QH, Wu Q, Lu YF, Shi JS. (2010) Icariin isolated from Epimedium brevicornum Maxim attenuates learning and memory deficits induced by d-galactose in rats. Pharmacol Biochem Behav 96:301-305.
24. Li L, Wang XM. (2008) Progress of pharmacological research on icariin. Zhongguo Zhong Yao Za Zhi 33:2727-2732.
25. Liao H, Jacob R. (2012) Chinese herbal drugs for erectile dysfunction through NO-cGMP-PDE5 signalling pathway. Zhonghua Nan Ke Xue 18:260-265.
26. Liu F, Xia M, Xu A. (2008) Expression of VEGF, iNOS, and eNOS is increased in cochlea of diabetic rat. Acta Otolaryngol 128:1178-1186.
27. Lombardi G, Nelli F, Celso M, Mencarini M, Del Popolo G. (2012) Treating erectile dysfunction and central neurological diseases with oral phosphodiesterase type 5 inhibitors. J Sex Med 9:970-985.
28. Luo Y, Nie J, Gong QH, Lu YF, Wu Q, Shi JS. (2007) Protective effects of icariin against learning and memory deficits induced by aluminium in rats. Clin Exp Pharmacol Physiol 34:792-795.
29. Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, Yarasheski KE, Bateman RJ. (2010) Decreased clearance of CNS beta-Amyloid in Alzheimer's disease. Science 330:1774.
30. Nie J, Luo Y, Huang XN, Gong QH, Wu Q, Shi JS. (2010) Icariin inhibits beta-Amyloid peptide segment 25-35 induced expression of beta-secretase in rat hippocampus. Eur J Pharmacol 626:213-218.
31. Paxinos G, Franklin K. (2001) The mouse brain in stereotaxic coordinates. Second Edition. New York: Academic Press.
32. Puzzo D, Staniszewski A, Deng SX, Privitera L, Leznik E, Liu S, Zhang H, Feng Y, Palmeri A, Landry DW, Arancio O. (2009) Phosphodiesterase 5 inhibition improves synaptic function, memory, and amyloid-beta load in an Alzheimer's disease mouse model. J Neurosci 29:8075-8086.
33. Rybalkin SD, Yan C, Bornfeldt KE, Beavo JA. (2003) Cyclic GMP phosphodiesterases and regulation of smooth muscle function. Circ Res 93:280-291.
34. Sabayan B, Zamiri N, Farshchizarabi S, Sabayan B. (2010) Phosphodiesterase-5 inhibitors: Novel weapons against Alzheimer's disease? Int J Neurosci 120:746-751.
35. Schulz E, Tsilimingas N, Rinze R, Reiter B, Wendt M, Oelze M, Woelken-Weckmüller S, Walter U, Reichenspurner H, Meinertz T, Münzel T. (2002) Functional and biochemical analysis of endothelial. (dys)function and NO/cGMP signalling in human blood vessels with and without nitroglycerin pretreatment. Circulation 105:1170-1175.
36. Selkoe DJ. (2002) Alzheimer's disease is a synaptic failure. Science 298:789-791.
37. Skovronsky DM, Lee VM, Trojanowski JQ. (2006) Neurodegenerative diseases: New concepts of pathogenesis and their therapeutic implications. Annu Rev Pathol 1:151-170.
38. Uthayathas S, Karuppagounder SS, Thrash BM, Parameshwaran K, Uppiramaniam V, Dhanasekaran M. (2007) Versatile effects of sildenafil: Recent pharmacological applications. Pharmacol Rep 59:150-163.
39. Xu HB, Huang ZQ. (2007) Icariin enhances endothelial nitric-oxide synthase expression on human endothelial cells in vitro. Vascul Pharmacol 47:18-24.
40. Xu RX, Wu Q, Luo Y, Gong QH, Yu LM, Huang XN, Sun AS, Shi JS. (2009) Protective effects of icariin on cognitive deficits induced by chronic cerebral hypoperfusion in rats. Clin Exp Pharmacol Physiol 36:810-815.
41. Zhou J, Zhou L, Hou D, Tang J, Sun J, Bondy SC. (2011) Paeonol increases levels of cortical cytochrome oxidase and vascular actin and improves behavior in a rat model of Alzheimer's disease. Brain Res 1388:141-147.
42. Zhou L, Zhu DY. (2009) Neuronal nitric oxide synthase: Structure, subcellular localization, regulation, and clinical implications. Nitric Oxide 20:223-230.
43. Zlokovic BV. (2011) Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci 12:723-738.